Compare
PMV Pharmaceuticals, Inc. vs Aardvark Therapeutics, Inc. vs Camp4 Therapeutics Corp vs Filana Therapeutics, Inc.
| Latest fiscal year | PMV Pharmaceuticals, Inc. PMVP | Aardvark Therapeutics, Inc. AARD | Camp4 Therapeutics Corp CAMP | Filana Therapeutics, Inc. FLNA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $0 | $3.50M | n/a |
| Revenue growth (YoY) | n/a | n/a | +436.5% | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/m | n/a |
| Net margin | n/a | n/a | n/m | n/a |
| Net income | -$77.74M | -$57.59M | -$80.40M | -$90.97M |
| EPS (Diluted) | -$1.48 | -$2.93 | -$2.65 | -$1.88 |
| Operating cash flow | -$73.58M | -$54.17M | -$29.55M | -$32.25M |
| Free cash flow | -$73.61M | -$54.27M | -$29.83M | -$32.83M |
| Cash & equivalents | $37.98M | $47.05M | $109.52M | $95.50M |
| Total assets | $116.56M | $117.18M | $117.81M | $118.36M |
| Total liabilities | $11.85M | $10.55M | $70.10M | $43.95M |
| Shareholders' equity | $104.71M | $106.63M | $47.70M | $74.40M |
| Return on year-end equity | -74.2% | -54.0% | -168.5% | -122.3% |
| Shares outstanding | 53.33M | 21.82M | 51.90M | 48.31M |
Revenue, most recent five fiscal years
| Fiscal year | PMV Pharmaceuticals, Inc. | Aardvark Therapeutics, Inc. | Camp4 Therapeutics Corp | Filana Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | $0 Ended 2025-12-31 | $3.50M Ended 2025-12-31 | $41.12M Ended 2013-12-31 |
| 1 year earlier | n/a | n/a | $652.0K Ended 2024-12-31 | $10.89M Ended 2012-12-31 |
| 2 years earlier | n/a | n/a | $350.0K Ended 2023-12-31 | $11.48M Ended 2011-12-31 |
| 3 years earlier | n/a | n/a | n/a | $16.81M Ended 2010-12-31 |
| 4 years earlier | n/a | n/a | n/a | $20.56M Ended 2009-12-31 |